Short Interest Update on Calithera Biosciences (CALA)

Calithera Biosciences (CALA) has 1,249,881 shares of shorts outstanding as on August 15, 2016, with 5 days left to cover or roll them over. On Jul 29, 2016, the open interest of short positions was 1,353,526 shares. The stock has a decent trading volume of 233,229 shares daily. The marginal decrease in the short positions is by -7.7%, which amounts to -103,645 shares. Short positions are 10.6% of the available float. The short interest information was released on Wednesday Aug 24th after the market close.

Calithera Biosciences (NASDAQ:CALA): The stock opened at $3.25 on Wednesday but the bulls could not build on the opening and the stock topped out at $3.39 for the day. The stock traded down to $3.12 during the day, due to lack of any buying support eventually closed down at $3.14 with a loss of -3.68% for the day. The stock had closed at $3.26 on the previous day. The total traded volume was 142,456 shares.


In a related news, The Securities and Exchange Commission has divulged that Hecht Curtis, officer (VP, BUS. & CORP. DEVELOPMENT) of Calithera Biosciences, Inc., had unloaded 970 shares at an average price of $6.58 in a transaction dated on November 16, 2015. The total value of the transaction was worth $6,383.

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Companys lead product candidate, CB-839, is an internally discovered, inhibitor of glutaminase, a critical enzyme in tumor metabolism. The Company is evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors. Its lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a therapeutic agent for the target. The Companys ongoing research efforts are focused on discovering additional product candidates against tumor metabolism and immunology targets.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.